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Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most used drugs in equine 
medicine, mainly to manage inflammation, endotoxemia, pain and fever (COOK and 
BLIKSLAGER 2015). NSAIDs work by inhibiting cycloxygenases (COX), particularly COX-1 
and COX-2, which are responsible for synthesizing prostanoids, which they are important to 
prevent gastrointestinal (GI) tract ulcers, enhance GI tract mucosal repair, and control and 
maintain GI tract and renal blood flow to correct hypovolemia (TOMLINSON and 
BLIKSLAGER 2004; MCCONNICO et al. 2008; COOK and BLIKSLAGER 2015). By 
inhibiting COX enzymes, the NSAIDs can subsequently cause side effects such as GI and urinary 
tracts ulcerations, right dorsal colitis, diarrhea in foals and renal papillary necrosis 
(MACALLISTER et al. 1993; MCCONNICO et al. 2008; COOK and BLIKSLAGER 2015). 
Renal papillary necrosis can be caused by overdose in healthy horses or recommended dose of 
phenylbutazone (PHZ) in water deprived horses. The PHZ inhibits local synthesis of 
prostaglandin E2 (PGE2) and prostaglandin I2 (PGI2), which in well hydrated patients can 
compensate the reduced renal blood flow to renal medulla by inducing vasodilatation, however, 
in dehydrated patients, even with recommended dose of PHZ, can lead to necrosis of renal 
papillae (GUNSON and SOMA 1983; MACALLISTER et al. 1993). Side effects such as 
neutrophilia, progressive increase in some of the serum values such as blood urea nitrogen 
(BUN), creatinine (S-Cr) and phosphate (P) have been observed in horses treated with large doses 
of PHZ (MACKAY et al. 1983). Urinary gamma glutamyl transferase (U-GGT):urinary 
creatinine ratio (U-GGT:U-Cr) and fractional excretion of sodium (FENa) can be used to detect 
the effect of PHZ on the kidney function (El-ASHKER et al. 2012). The urinary tract is usually 
exposed to the pathogens, urinary mucus, which is produced by renal pelvis, and IgA play an 
important role in protecting the urinary tract. The mucus layer of mucous membranes is a 
sufficient defense mechanism to prevent adhesion of bacteria to the urinary epithelial cells and 
clear them from the system (HANSSON 2012). Previous studies have shown that urinary tract 
infections (UTIs) in horses are associated with any lesions which interfere with urine flow or 
being able to cause urinary mucosal damage (SAULEZ et al. 2005, SQUINAS and BRITTON 
2013). Recent reports have indicated different information regarding the ability of 
phenylbutazone to affect the protective mechanisms of the urinary system, while one report has 
shown that long-term use of phenylbutazone can cause ulcerative cystitis in horses, presumably 
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by reducing prostaglandins (ALEMAN et al. 2011), another study has reported that using 
phenylbutazone for 7 days has no effect on COX-1 and COX-2 expression in bladder mucosa 
(NIETO et al. 2012). In a study performed on children urine, it has been found that secretory 
immunoglobulin A (IgA) concentration increased in individuals with UTIs, and can be used as a 
marker to identify type of UTIs (DEO and VAIDYA 2004). 
Renal failure in horses can occur as a result of decreased renal perfusion (prerenal failure), or 
cellular damage of the glomeruli or the tubules or tubular obstruction or tubulointerstitial 
inflammatory process (renal failure), or renal failure can be caused by interfering or obstruction 
of the urine outflow (HALBMAYR and SCHUSSER 1999; SCHULZE et al. 2004). Prerenal 
failure is the most common type of renal failure in horses, it is caused by decreased cardiac 
output or/and increased renal vascular resistance. Causes of decreased cardiac output in horses 
include diarrhea, endotoxemia, acute blood loss due trauma, septic shock, and prolonged 
exercise, which can cause decreased renal blood flow and glomerular filtration rate, and 
subsequent azotemia and electrolytes imbalances (WALDRIDGE 2010). NSAIDs can also cause 
prerenal azotemia in dehydrated horses, as they inhibit renal prostaglandins, which help to 
compensate decreased renal blood flow as they are vasodilatory mediators, therefore, using 
NSAIDs in dehydrated patients may exacerbate renal hypoperfusion and subsequent azotemia 
(MACALLISTER et al. 1993). 
As NSAIDs are commonly used in equine practices, and little is known about their effects on 
the urinary defense mechanisms, accordingly, the objective of the present study was to 
investigate the influences of using flunixin meglumine, metamizole, and phenylbutazone on 








2.1. Physiology of Prostanoids in Different Organs 
Prostanoids are synthesized from an unsaturated fatty acid, arachidonic acid, by prostaglandin 
G/H synthase and cycloxygenases (COX), which exist in two different isoforms, COX-1 and 
COX-2, and they are expressed by most body cells. The end products of the prostanoids synthesis 
are prostaglandin D2 (PGD2) (in the mast cells, brain and respiratory tract), prostaglandin E2, 
(PGE2) (in kidney, brain, platelets and vascular smooth muscle fibers), prostaglandin F2a (PGF2a) 
(in uterus, vascular smooth muscle fibers, respiratory airway and eye), prostacyclin (PGI2) (in the 
endothelia, kidney, platelets and brain) and thromboxane A2 (TXA2) in platelets, macrophages, 
vascular smooth muscle fibers and kidney. Production of prostanoids increased significantly 
during the inflammatory processes mediated mainly by COX-2, with COX-1 participating in 
early phase of acute inflammation, while COX-2 mediates its products several hours after the 
inflammation begins. PGE2 and PGI2 are the most formed pro-inflammatory prostanoids, both of 
them increase edema formation and leukocytes infiltration by increasing blood flow (MCADAM 
et al. 2000; SMYTH et al. 2009). Prostanoids can cause pain in two different ways, peripherally 
or centrally. Cells of damaged tissues and infiltrated immune cells release many mediators such 
as cytokines, chemokines, bradykinins, prostaglandins (e.g. PGE2 and PGI2) and others. PGE2 
and PGI2 decrease the peripheral threshold of nociceptor sensory neurons to stimuli. Centrally, 
the expression of COX-1 and COX-2 in the spinal cord, in response to peripheral pain, leads to 
release of PGE2, PGF2a and PGI2 which amplify the central sensitization to pain (CHEN et al. 
2013). 
2.1.1. Gastrointestinal System 
The main prostanoids produced by mammalian gastric mucosa are PGE2 and PGI2, and to lesser 
extent PGF2a, PGD2 and TXA2. The prostaglandins protect gastric mucosa by stimulating the 
mucus and bicarbonate secretion in the stomach, improving the mucosal phospholipid layer and 
reducing epithelial cells permeability to luminal acid. Prostaglandins E and I are powerful 
vasodilator, which increase blood flow to the gastric mucosa. COX-1 is responsible for 
maintaining blood flow in healthy mucosa, while COX-2 mediates synthesis of prostaglandins in 
cases of mucosal injury. Prostaglandins inhibit releasing a couple of inflammatory mediators that 
contribute to the mucosal injury, such as histamine, tumor necrosis factor-a, platelet activating 
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factor from mast cells, releasing of tumor necrosis factor-a and interleukin-1 from macrophages, 
releasing of leukotriene B4 and interleukin-8 from neutrophils. All these mediators have been 
proofed to be suppressed by PGE2. Gastric ulcer healing is derived primarily from COX-2. 
Ability of prostaglandins to heal gastric ulcers has been attributed to their abilities to inhibit 
gastric acid secretion, increase blood flow to the ulcer margin (where the epithelial cells 
regeneration takes place), stimulating mucus and bicarbonate secretion and stimulating 
angiogenesis through vascular endothelial growth factor (WALLACE 2008). Prostaglandins 
regulate intestinal smooth muscles contractility. PGE2 causes intestinal longitudinal smooth 
muscles contraction and circular muscles relaxation, while PGF2a causes longitudinal and circular 
smooth muscle contractions (HOOGMOED et al. 2000). Prostaglandins are also important for 
intestinal mucosal barrier repair after ischemic injury. The first response to intestinal mucosal 
injury is contraction of the intestinal villi, which takes place in two phases, the first phase is 
mediated by enteric nervous system, the second phase is mediated by prostaglandins. The second 
response is epithelial restitution, which is not depended on the prostaglandins. However, the 
prostaglandins stimulate recruitment of the tight junctions to close the apical paracellular space of 
the epithelial cells in the third process of the repairing the intestinal mucosal damage 
(MARSHALL and BLIKSLAGER 2011). 
2.1.2. Musculoskeletal System 
Prostaglandins, PGE2 in particular, stimulate osteoprogenitor proliferation and differentiation. 
Administration of prostaglandins in vivo increases periosteal and endosteal responses which 
increase bone mass (JEE and MA 1997; GENETOS et al. 2011). Prostaglandins inhibition delays 
bone fracture healing and can lead to non-unions (GIANNOUDIS et al. 2000; SIMON et al. 
2002; BURD et al. 2003; GERSTENFELD and EINHORN 2004). Joint inflammation, injury, 
cells damage, vascular distention, exercise or stress cause prostaglandins release. Equine 
chondrocytes produce PGE2 in vitro when they are subjected to adverse conditions. PGE2 
production in the joint is very rapid, with peaking 2-9 hours after onset (VAN DEN BOOM et al. 
2005). It has been suggested that PGE2 acts as a mediator of the inflammatory process and 
hyperalgesia, through vasodilatory effect, increasing vascular permeability, and sensitization of 
joint nociceptors in horses (PALMER and BERTONE 1994). PGE seems to be associated with 
increased metabolic activity in the cartilage and bone resorption associated with osteomyelitis, 
whereas PGF is chondro-protective (KALLINGS 1993). Proteoglycans are the main component 
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of the cartilage matrix. During osteoarthritis, the proteoglycans undergo degradation accompany 
by inability of chondrocytes to synthesize new matrix. In a study to assess the effect of oral 
administration of phenylbutazone (PHZ) for 14 days on synthesis of proteoglycans and 
chondrocytes inhibition by interleukin-1b (IL-1b) in articular cartilage explants showed 
significant decrease in proteoglycan synthesis in articular cartilage culture explants from healthy 
individuals to the same degree of that induced by in vitro IL-1b exposure (BELUCHE et al. 
2001). In another experiment, using PHZ (4.4 mg/kg, PO, q12h, for 30 days) significantly 
decreased mineral apposition rate in the tibia and seemed to decrease the healing rate of the 
unicortical bone defects in horses (ROHDE et al. 2000). 
2.1.3. Kidneys 
Both COX-1 and COX-2 are expressed in the kidney, with COX-1 is expressed mainly by 
epithelia of the glomeruli, arteriolar endothelia, cortical and medullary collecting ducts and 
mesangial cells, while COX-2 is expressed in the cortical ascending limb cells, macula densa and 
medullary interstitial cells. PGE2, PGI2, PGF2a and TXA2 are the most abundant prostanoids in 
the kidney. Under normal conditions, prostanoids have little effects on renal blood flow and 
glomerular filtration rate (GRF). However, under some conditions which compromise arterial 
blood volume, such as dehydration, congestive heart failure, cirrhosis with ascites, and nephrotic 
syndrome, normal kidneys functions depend on the effect of the prostanoids to restore normal 
renal blood flow. In the cases of hypovolemia, the body produces catecholamines, angiotensin, 
and vasopressin which act as vasoconstrictors. The kidneys depend on the effects of prostanoids 
which act as vasodilators and maintain normal renal blood flow. Renal PGE2 maintains GFR by 
vasodilating the afferent arteriole. It has been suggested that COX-2 derived prostanoids play 
important role in renal sodium excretion and maintaining blood pressure, therefore, using COX-2 
selective inhibitors results in sodium retention and edema formation. Also, COX-2 inhibitors 
decrease renal medullary blood flow, which causes sodium retention and subsequent 
hypertension (HAO and BREYER  2008; SMYTH et al. 2009). 
2.2 Effects of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used in human and veterinary 
medicines for their analgesic, anti-inflammatory and antiendotoxic properties. Prostanoids 
decrease pain threshold for neural conduction of the pain pathway, therefore increase the 
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sensation of pain. PGE2 sensitizes nociceptors at the end of sensory neurons. COX inhibitors 
decrease pain through reducing prostanoids production in the spinal cord and subsequent 
decrease central nervous system sensitization. The emergence of COX-2 inhibitors helps to 
provide the analgesic effects and avoid inhibiting COX-1, however, because the overlap between 
COX-1 and COX-2 functions, questions about the efficacy of COX-2 inhibitors have been raised. 
One study showed that using meloxicam (COX-2 inhibitor) at dose of 0.6 mg/kg, iv, q12h, did 
not inhibit the intestinal mucosal repair, however, provided almost the same level of analgesia as 
flunixin meglumine (FM) (1.1 mg/kg, IV, q12h) when the experimental horses were judged by 
clinician and combined blinded pain score, however, provided significantly less analgesia when 
judged by blinded observer. In another study using etodolac (COX-2 inhibitor) (23 mg/kg, iv, 
q12h) inhibited the small intestinal mucosal repair, suggesting that no advantage of using 
etodolac over FM (1.1mg/kg, IV, q12h) in horses. In experimental study, a highly selective COX-
2 inhibitor firocoxib (0.09 mg/kg, IV, q24h) and FM were used in horses with small intestinal 
strangulating obstruction, the study concluded that firocoxib provided the same level of analgesia 
as FM, and also the FM caused significant increase in intestinal permeability to 
lipopolysaccharide (LPS) (TOMLINSON et al. 2004; COOK et al. 2009; NAYLOR et al. 2014; 
COOK and BLIKSLAGER 2015). FM is the most common used NSAID to reduce signs of 
endotoxemia in horses. In early study, pretreatment with FM (1 mg/kg) reduced the clinical signs 
of induced endotoxemia compared with PHZ (2 mg/kg). Several other studies have explained the 
effects of FM on cardiovascular responses to endotoxemia. Endotoxin increases the prostanoids 
TXA2, 6-keto PGF1a and PGI2. Pretreatment with FM has been found to prevent increase in these 
prostanoids by endotoxin. Although the role of FM in reducing the effects of inflammatory 
response of the endotoxemia by inhibiting the prostanoids, it has no effect to other inflammatory 
mediators such as tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) (BOTTOM et al. 
1981; OLSON et al. 1985; MOORE et al. 1986; JACKMAN et al. 1994; BASKETT et al. 1997; 
COOK and BLIKSLAGER 2015). 
2.3. Side Effects of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) 
Gastrointestinal ulceration is the most common side effect of using NSAID. It has been found 
that COX-1 was expressed in horses with normal nonglandular portion of the stomach and 
reduced in horses with ulcerated lesions in the gastric nonglandular portion, where COX-2 was 
only expressed in the ulcerated stomach, this study indicated that NSAIDs should not use in 
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horses with gastric ulcers. Using NSAIDs in patients with intestinal mucosal injury may delay 
their repair, as prostaglandins play an important role in intestinal injury repair. It has been found 
in a study where ischemia was in horses´ jejunum that FM delayed intestinal mucosal repair, but 
did not increase absorption of the LPS. However, using selective COX-2 inhibitors, such as 
firocoxib, meloxicam, did not delay the repair of the small intestinal ischemia. Other studies, on 
the effect of FM on recovery of the ischemia of colonic mucosa in horses, have found that the FM 
did not delay its repair (TOMLINSON and BLIKSLAGER 2004; LITTLE et al. 2007; COOK et 
al. 2009; MATYJASZEK, et al. 2009; RODRIGUES et al. 2010; MORTON et al. 2011; COOK 
and BLIKSLAGER 2015). The most NSAIDs associated with right dorsal colitis is PHZ, 
symptoms may include colic, diarrhea, and protein losing enteropathy. Hypoalbuminemia is one 
of the earliest symptoms, it can appear as early as 3 days after starting using PHZ. 
Transabdominal ultrasound can show increased mural thickness of the right dorsal colon. 
Neutropenia, changes in right dorsal colon arterial blood flow and changes in volatile fatty acids 
production have also been noticed (KARCHER et al. 1990; COHEN et al. 1995; JONES et al. 
2003; MCCONNICO et al. 2008). 
TXA2 and prostacyclin are contributing to hemostasis in two opposite mechanisms. TXA2 is 
synthesized by platelets, mediated only by COX-1. TXA2 causes platelets aggregation and 
vasoconstriction. Prostacyclin is synthesized by endothelial cells, mediated by COX-2 and causes 
vasodilation and prevents platelets aggregation (PATRIGNANI et al. 1999; FOSSLIEN 2005; 
ROUBILLE et al. 2013). Several of studies in human medicine revealed the side effects of COX-
2 selective NSAIDs, such as firocoxib, on the cardiovascular system, mainly because COX-2 
inhibition shifts TXA2-prostacyclin balance to the direction of TXA2, which results in platelets 
aggregation and vasoconstriction. There are no documented cardiovascular side effects for PHZ 
and FM in horses. However, disseminated intravascular coagulopathy (DIC) is well documented 
in horses. DIC can be caused by different kinds of local or systemic inflammations, such as 
parasitic migration, colitis, small intestinal strangulation, and pleuropneumonia. Severe 
gastrointestinal disorders in horses usually results in fibrin deposits in different organs consistent 
with microthrombosis, multiorgan failure and DIC. Thromboembolism can occur in horses as 
jugular vein thrombosis, pulmonary arteries thrombosis, mesenteric veins thrombosis, or hepatic 
vein thrombosis. Aspirin, a COX-1 inhibitor, has been used for thromboprophylaxis in horses. 
Aspirin at 5 mg/kg, PO, q24h dose has significantly decreased serum thromboxane B2 (TXB2) in 
horses (COTOVIO et al. 2007; BRAINARD et al. 2011). 
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Foals are predisposed to NSAIDs´ side effects, probably because of different pharmacokinetics of 
NSAIDs compared to adults. Using PHZ at 2.2 mg/kg dose in foals has been found to have a 
longer half-life and a lower total clearance when compared to adults (WILCKE et al. 1993). In 
another study assessing the route of administration of FM in foals, using 1.1 mg/kg, po dose for 
30 days caused oral ulceration, while those received the same dose intramuscular (im) did not 
show oral ulceration, however, both routes of administration caused gastric glandular ulcers 
(TRAUB-DARGATZ et al. 1988). In another experiment, different doses of FM (0.55 – 6.6 
mg/kg for 5 days) were used in neonatal foals, diarrhea was the most common side effect, which 
was not dose-dependent, hypoproteinemia associated with gastrointestinal ulceration was also 
noticed, most of these ulcers were in the gastric glandular region (CARRICK et al. 1989). Study 
on oral meloxicam, using the same dose as adult horses (0.6 mg/kg, q12h), in foals has provided 
the same therapeutic levels with no side effects noted even at higher doses (1.8 mg/kg, q12h, for 
7 days) (RAIDAL et al. 2013). Blood analysis, urinalysis, and gastroscopy did not show side 
effects in foals of 36 hours of age, when treated with firocoxib at dose 0.1 mg/kg, q24h, PO for 9 
days (HOVANESSIAN et al. 2014). 
Inhibition of renal PGI2 and PGE2 by using of NSAIDs in hydrated horses has little effects on 
renal perfusion. However, in dehydrated patients, inhibition of PGI2 and PGE2 result in 
vasoconstriction of the afferent arterioles, redirecting the blood flow to the renal cortex, and 
reduced or loss of renal medullary perfusion, which results in a characteristic lesion of renal 
papillary necrosis (READ 1983; MACALLISTER et al. 1993; WHELTON 1999; KIM 2008). 
PGE2 decreases water and sodium reabsorption at the thick ascending loop of Henle (EPSTEIN 
2002), therefore, inhibition of PGE2 by NSAIDs would result on sodium retention. The effect of 
PHZ on the effect of furosemide on urinary electrolytes secretion has been assessed. PHZ 
significantly decreased urinary sodium and chloride excretion by 40% and 32% respectively 
when compared to patients treated with furosemide alone (DYKE et al. 1999). These findings 
should be taken into consideration when treating critically ill patients with both NSAIDs and 
sodium rich intravenous fluids for long time, as this combination might result in sodium retention 
and edema formation (COOK and BLIKSLAGER 2015). In human medicine, it has been found 
that using COX-2 selective NSAIDs is safer on the kidneys than nonselective NSAIDs. Long 
term using of celecoxib (a COX-2 selective NSAIDs) for patients with osteoarthritis or 
rheumatoid arthritis had significantly less renal toxicity than ibuprofen and diclofenac 
(nonselective NSAIDs) (SILVERSTEIN et al. 2000). No such study has been conducted to 
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evaluate the effect of COX-2 selective NSAIDs on the kidney in hypovolemic horses, therefore, 
to avoid nephrotoxicity, it is advisable to perform a complete physical examination to evaluate 
vascular volume through pulse strength, jugular fill, and volume and frequency of urination, then 
correct the intravascular volume prior to NSAIDs administration (COOK and BLIKSLAGER 
2015). 
2.4. Urinary Tract Infections (UTIs) and Defense Mechanisms 
Urinary tract infections (UTIs) are caused by microbial invasion and colonization of the kidney, 
ureter, urinary bladder, and proximal urethra. UTIs can be divided into upper UTI, which 
involves the kidneys and ureters, and lower UTI, involving the urinary bladder and urethra. The 
incidence of UTIs is low in horses, particularly upper UTIs. Lower UTIs are the most common 
type of UTIs seen in horses, and usually caused by disrupted urine flow, mostly urinary stone or 
partial obstruction of the urinary tract. Escherichia coli, Proteus spp., Klebsiella spp., 
Enterobacter spp., Pseudomonas aeruginosa, Streptococcus equi subsp. zooepidemicus, and 
Streptococcus equisimilis are the most common bacteria involved in UTIs, and to a lesser extent 
Staphylococcus and Corynebacterium spp. Enterococcus spp. has been isolated from horses 
experiencing urine flow abnormalities or horses were urinary catheterized. It is common to 
isolate more than one bacterial species. Because of their shorter urethra and potential fecal 
contamination from poor perineal conformation, female horses are more prone to develop UTIs 
than male horses. Other UTIs’ risk factors include bladder paralysis, urolithiasis, urethral trauma. 
Cystitis may develop as a result of urolithiasis, bladder paralysis, or neoplasia. Urinary bladder 
paralysis can be caused by trauma or some neurologic diseases such as neuritis of the Cauda 
equine, equine protozoal myeloencephalitis or equine herpesvirus-1 (ZIMMEL 2014). One of the 
body’s defense mechanisms to protect itself against microbes and antigens is secretory 
immunoglobulin A (sIgA). sIgA is secreted in different body fluids, such as saliva, milk, 
gastrointestinal and respiratory secretions. Immunoglobulin A (IgA) is synthesized by plasma 
cells in the lamina propria of the mucous membranes or connective tissues of secretory glands. 
Some of these sIgA diffuse through the basement membrane into the epithelial cells, then 
transcytosed to the apical surface of the epithelial cells, then secreted as sIgA. sIgA in saliva is 
used as a stress marker and effects of stress on the immune system (TSUJITA and MORIMOTO 
1999; CORTHÉSY 2013). It has been found that bronchial epithelial abnormalities lead to 
localized sIgA deficiency in chronic obstructive pulmonary disease (COPD) airways, which may 
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cause persistent airways inflammation (POLOSUKHIN et al. 2011). Intestines of human neonates 
are sIgA deficient and need around 30 days postpartum to develop the ability to produce effective 
levels of sIgA. The activation of intestinal plasma cells depends on intestinal colonization by 
Bifidobacteria and Lactobacilli. During this period, neonates depend on their mothers’ breast 
milk sIgA, which protects them against the surrounding environmental antigens such as toxins, 
microorganism, and dietary antigens (HE et al. 2007; WALKER 2010). Measuring sIgA in 
children’s urine can also be used to detect UTI, type of infection, and degree of the host’s 
response to the infection (DEO and VAIDYA 2004). 
Equine urinary mucus is produced in renal pelvis and proximal ureter that helps to lubricate the 
lower urinary tract to minimize adherence of calcium carbonate crystal to the epithelium lining 
the ureters, bladder, and urethra which decreases the chances of urolithiasis and UTIs 
(WALDRIDGE 2010). Mucus is very important line of defense, as it removes and clears the 
potential microorganisms and antigens from the mucous membranes. In respiratory system, 
mucus-secreting ciliated cells produce the mucus and chloride pumps osmotically help the mucus 
hydration, then the cellular cilia move the mucus and the trapped antigens from the bronchi and 
trachea to the pharynx to be swallowed, the same mechanism takes place in the nose and 
paranasal sinuses, where the mucus being carried to the oropharynx to be swallowed (COHEN 
2006; HARKEMA et al. 2006). Uterine epithelia provide a non-toxic mechanism to remove 
potential antigens and facilitating a suitable environment for early equine embryo by secreting 
sIgA to attach to the pathogens and trapped them in the uterine mucus, then cleared mechanically 
(CAUSEY 2007). In the stomach, the mucus’s main function is to protect the gastric mucosa acid 
and pepsin (ALLEN et al. 1986; KÖLLER et al. 2010), but also it prevents bacteria from 
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The current study describes the effects of using flunixin meglumine (FM), metamizole (MZ) (for 
gastrointestinal pain) or phenylbutazone (PHZ) (for orthopedic pain) on renal function parameters 
in horses. Our results on equine kidney functions using FM, MZ and PHZ were compared with 
findings in the literature (MACALLISTER et al. 1993; EL-ASHKER et al. 2012). The limitation 
of this study is the samples were collected on days 3-5 of treatment, no samplings were 
performed before treatment, as these horses were patients brought to the clinic to be treated for 
their gastrointestinal and orthopedic conditions. Because the patients in groups 1 and 2 were 
treated with lactated ringer’s solution, the serum Na and K were within normal range in these 
groups, which indicate that these NSAIDs may have no effects on serum Na and K, despite their 
effects on FENa and FEK. The NSAIDs used did not influence the reabsorption of inorganic 
phosphate in the proximal tubules, as the FEiP values were not increased in all groups compared to 
control group. Some horses of group 2 developed a mild to moderate form of hypomagnesemia in 
comparison with the control group, but still within the reference range, which, in combination 
with a mildly increased FEMg and reduced U-Cr:S-Cr ratio, suggests that using MZ may slightly 
reduce the reabsorption of Mg at the thick ascending loop of Henle, although FEMg in this group 
is not significantly different from the control group. It has been reported that 50 to 70 % of the 
Mg in horses is reabsorbed in the thick ascending loop of Henle (TORIBIO 2007). Normal S-Cr, 
glucose, total protein and BUN concentrations of all groups (compared to the control group) 
indicate that renal side effects caused by FM, MZ and PHZ cannot be detected using these serum 
biochemical parameters on the third or until the fifth day of administrations. A previous study, in 
which PHZ was used at a dose of 4.4 mg/kg, i.v., q8h, for 12 days, reported that using PHZ for 8 
days caused significant hypoproteinemia and hypoalbuminemia, and further use of PHZ up to 12 
days caused even more reduction in serum total protein and albumin concentrations, whereas FM 
had no effects on equine serum protein concentrations (MACALLISTER et al. 1993). The 
difference from our study is that the PHZ dose was used three times a day and length of treatment 
was longer in the latter study, which suggests that prolonged and more frequent usage of PHZ can 
lead to protein-losing nephropathy. Urinary specific gravity is affected by the concentration of 
the solutes in the urine. Decreased concentrations of UUN, U-Cr, K, Ca and Cl in group 2 caused 
a urine specific gravity less than 1.035 (control group), however, MZ does not cause polyuria, but 
the horses with colic treated with laxatives could have more water intake after resolving the 
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impaction (SPALLEK et al. 2011). Therefore, group 2 showed significantly decreased urinary 
FENa, which is probably a renal compensatory mechanism. The FECl and FEK were significantly 
decreased in group 2, which could be influenced by the laxative treatment with sodium sulphate 
(1.8 %) (SPALLEK et al. 2011). The loop of Henle controls urine concentration via a 
countercurrent multiplication mechanism, which depends mainly on concentrations of urea and 
sodium salts in the renal medullary interstitial fluids (SADOWSKI and DOBROWOLSKI 2003; 
SCHOTT 2010). In the present study, both U-Cr and UUN concentrations were significantly 
lower in both groups 1 and 2 than in the control group. This could be partially because of the 
slightly low BUN concentrations of these two groups, which could be due, in turn, to the i.v. fluid 
treatment (group 1) and more water intake (group 2) rather than loop of Henle dysfunction. Using 
PHZ did not affect the UUN concentration, however, it caused a significant increase of FECa and 
FEMg in comparison with the control group, which suggests that using of PHZ in horses with 
orthopedic pain can affect the reabsorption of Ca and Mg at the thick ascending loop of Henle. 
Previous studies pointed to renal crest necrosis as a side effect of using PHZ, since the PHZ can 
cause inadequate blood supply in the renal medulla in water-deprived horses (GUNSON and 
SOMA 1983; MACALLISTER 1993). However, the difference between the latter studies and our 
study is that, unlike these two studies, the horses in group 3 of our study were hydrated (as their 
PCV showed), and these horses were administered the recommended dose of PHZ. The dosage of 
PHZ used caused a high-grade increase of the U-GGT:U-Cr ratio in group 3 in comparison with 
the control group, but it is still within the normal range and does not indicate a damaging effect 
on brush border cells of the renal proximal tubular epithelium. Only a high U-Pro:U-Cr ratio can 
be used to detect glomerular or tubular dysfunction. The U-Pro:U-Cr ratio of group 1 and 2 were 
significantly increased compared with the control group, which suggests a mild tubular 
dysfunction. Our results suggest that the concentration of the 3rd quartile of the urine protein was 
higher than the normal range only in group 1 (FM). In an experimental study to investigate the 
effect of daily FM administration for five days on clinical and clinicopathological parameters in 
foals, the FM did not affect the PCV in the foals treated (CARRICK et al. 1989). One of the side 
effects of PHZ in horses is anorexia; as the horses treated with PHZ become anorectic, they drink 
inadequate amounts of water, which causes the urine to be concentrated, which appeared in the 
specific gravity of the urine in this group compared with the control group. This suggestion is 
consistent with another report that PHZ can cause anorexia in the horses treated and subsequent 
progressive hypercreatininemia (MACKAY et al. 1983). However, horses treated with PHZ in 
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this study were not anorectic and had no hypercreatininemia. Horses in groups 1 and 2 showed no 
significantly decreased medians of urinary mucus concentrations, however, their mucus:U-Cr 
ratios were within the same range compared with the control group. Horse’s urine is rich in 
mucus, mainly to prevent the formation of urinary stones and subsequent UTIs. A significant 
increase in the IgA:U-Cr ratios of the horses in group 1 and 2 has been observed in this study. 
Mucosal IgA is secreted by B lymphocytes, then transported through epithelial cells into the 
organs’ lumen due to mucosal stimulation (TEZUKA et al., 2007; LEWIS et al., 2010). The 
increased urinary IgA concentrations in both groups 1 and 2 could be caused by the influence of 
FM or MZ on the function of the proximal tubules.  
This study illustrates the effects of the NSAIDs used most commonly on the kidneys’ functions, 
and urinary mucus and IgA secretions in horses. Parameters such as U-Pro:U-Cr and U-GGT:U-
Cr ratios and FEMg, in combination with other clinical and clinicopathological values, can be used 
to detect dysfunction caused by FM, MZ and PHZ in the renal proximal tubules and the loop of 
Henle in equine kidneys. The renal pelvis can increase urinary mucus secretion, presumably as a 
preventive mechanism against the necrotic effect of PHZ in the adjacent renal papillae. Different 
possibilities could be attributed to the elevated urinary IgA secretion, due to glomerular and 
tubular inflammatory reaction or leaked through damaged renal glomeruli, therefore, further 
investigations regarding urinary immune responses are required. 
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Introduction: Nonsteroidal anti-inflammatory drugs (NSAIDs) are one of the most used drugs in 
equine medicine, mainly used to treat inflammation, endotoxemia, pain or fever. NSAIDs inhibit 
cyclooxygenases which induce to synthesize prostanoids. But NSAIDs have side effects to renal 
functions too. 
Objectives: The current study was carried out to investigate the effects of the most common used 
NSAIDs on urinary parameters in horses.  
Materials and Methods: Thirty healthy horses were used as a control group and 20 horses with 
left dorsal displacement, left ventral impaction or lameness of using either flunixin meglumine 
(FM), metamizole (MZ) or phenylbutazone (PHZ) have been assigned to groups 1, 2 or 3, 
respectively. Creatinine, urea nitrogen, glucose, protein and electrolytes were measured in serum 
and urine including GGT using an automatic analyzer. Fractional excretions (FE) of sodium, 
chloride, potassium, calcium, magnesium and inorganic phosphate, in addition to urinary protein 
(U-Pro):U-Cr and urinary gamma glutamyl transferase (U-GGT):U-Cr ratios were calculated. 
Urinary mucus and IgA concentrations were measured and their ratios to the urinary creatinine 
were calculated. The data were statistically analyzed using Shapiro-Wilks test, descriptive 
statistics, Kruskal-Wallis one-way analysis of variance and Dunn’s test. Significance was set at P 
£ 0.05. 
Results: The FEMg was significantly higher in group 3 (P < 0.033) compared to the control 
group. The U-GGT:U-Cr ratio was also significantly higher in group 3 (P < 0.001) compared 
with the control group. The U-Pro:U-Cr ratio was significantly higher in groups 1 and 2 (P < 
0.007 and P < 0.001, respectively) than in the control group. PHZ group had a significantly 
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increase in mucus:U-Cr ratio (P < 0.005). Significant increases were observed regarding the 
IgA:U-Cr ratio in groups 1 (P < 0.007) and 2 (P < 0.014). 
Conclusions: Long-term use of PHZ has an influence on the renal ascending limb of the loop of 
Henle, and all these drugs could have effects on the proximal tubules. Phenylbutazone causes an 
increase in urinary mucus secretion, probably as a protective mechanism against the necrotic 
effect in renal pelvis of PHZ. Parameters such as U-Pro:U-Cr and U-GGT:U-Cr ratios and FEMg 
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Einleitung: Nichtsteroidale, antiphlogistische Medikamente (NSAIDs) werden in der 
Pferdemedizin sehr häufig eingesetzt, um Entzündungen, Endotoxämie, Schmerz oder Fieber zu 
behandeln. NSAID inhibieren Enzyme der Cycloxygenase, die die Prostaglandinsynthese 
herbeiführen. Jedoch haben NSAIDs auch Nebenwirkungen auf die Nierenfunktionen. 
Ziele: Die aktuelle Studie untersuchte die Wirkungen der häufig eingesetzten NSAID auf die 
Nierenfunktionen bei Pferden.  
Material und Methoden: Dreißig gesunde Pferde wurden als Kontrolle verwendet, und 20 
Pferde mit Verlagerung der linken Kolonlagen über das Milz-Nieren-Band, Verstopfung der 
linken ventralen Längslage des großen Kolons oder Lahmheit erhielten Flunixin Meglumin (FM), 
Metamizol (MZ) oder Phenylbutazon (PHZ), wobei diese in  den Gruppen 1, 2 und 3 zugeordnet 
wurden. Kreatinin, Harnstoff, Glukose, Protein und Elektrolyte wurden im Serum und Harn 
inklusive GGT unter Verwendung eines automatischen Analysengerätes gemessen. Fraktionelle 
Exkretion (FE) von Natrium, Chlorid, Kalium, Calcium, Magnesium und anorganischem 
Phosphat wurden zusätzlich zu Urinprotein (U-Pro): U-Cr und Urin-Gamma-Glutamyltransferase 
(U-GGT):U-Cr-Verhältnissen berechnet. Die Urinschleim- und IgA-Konzentrationen wurden 
gemessen und deren Kreatinin-Urin-Verhältnisse berechnet. Die Daten wurden mittels Shapiro-
Wilks-Test, deskriptiver Statistik, Kruskal-Wallis-Einweganalyse der Varianz und Dunn-Test 
statistisch analysiert. Die Signifikanz wurde auf P≤0,05 gesetzt. 
Ergebnisse: Die FEMg war signifikant höher in Gruppe 3 (P < 0,033) im Vergleich zur 
Kontrollgruppe. Das U-GGT: U-Cr-Verhältnis war in der Gruppe 3 (P < 0,001) im Vergleich zur 
Kontrollgruppe ebenfalls signifikant höher. Das U-Pro: U-Cr-Verhältnis war signifikant höher in 
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den Gruppen 1 und 2 (P < 0,007 bzw. P < 0,001) als in der Kontrollgruppe. PHZ-Gruppe hatte 
eine signifikante Zunahme des Urinschleim:U-Cr-Verhältnisses (P < 0,005). In den Gruppen 1 (P 
< 0,007) und 2 (P < 0,014) wurden signifikante Zunahmen des IgA:U-Cr-Verhältnisses 
beobachtet. 
Schlussfolgerungen: Die Anwendung von PHZ wirkt sich auf den aufsteigenden Teil der Henle-
Schleife aus und alle NSAID können die proximalen Tubuli beeinflussen. Phenylbutazon 
verursacht eine Zunahme der Sekretion von Harnschleim, wahrscheinlich als Schutzmechanismus 
gegen die nekrotischen Wirkungen von PHZ im Nierenbecken. Parameter wie U-Pro:U-Cr und 
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